Autolus Therapeutics (NASDAQ:AUTL) Trading 3.7% Higher

Autolus Therapeutics plc (NASDAQ:AUTL) shot up 3.7% during trading on Thursday . The stock traded as high as $5.25 and last traded at $5.02. 215,735 shares changed hands during trading, a decline of 86% from the average session volume of 1,496,267 shares. The stock had previously closed at $4.84.

Wall Street Analysts Forecast Growth

Several research analysts recently issued reports on AUTL shares. Needham & Company LLC reissued a “buy” rating and set a $9.00 target price on shares of Autolus Therapeutics in a research note on Friday, April 12th. Truist Financial raised their target price on Autolus Therapeutics from $10.00 to $11.00 and gave the company a “buy” rating in a research note on Tuesday, April 9th. One equities research analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $8.16.

Autolus Therapeutics Price Performance

The company has a market capitalization of $1.33 billion, a P/E ratio of -4.18 and a beta of 1.90. The firm has a fifty day moving average price of $5.95 and a 200-day moving average price of $5.08.

Autolus Therapeutics (NASDAQ:AUTL) last posted its quarterly earnings results on Thursday, March 14th. The company reported ($0.44) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.26) by ($0.18). On average, research analysts forecast that Autolus Therapeutics plc will post -0.71 EPS for the current year.

Institutional Trading of Autolus Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in AUTL. Two Sigma Advisers LP purchased a new stake in Autolus Therapeutics during the 1st quarter valued at about $25,000. BNP Paribas Financial Markets increased its position in shares of Autolus Therapeutics by 337.3% in the fourth quarter. BNP Paribas Financial Markets now owns 4,268 shares of the company’s stock valued at $27,000 after acquiring an additional 3,292 shares during the period. CI Private Wealth LLC bought a new stake in shares of Autolus Therapeutics in the fourth quarter worth about $28,000. Sei Investments Co. bought a new position in Autolus Therapeutics during the 4th quarter valued at approximately $29,000. Finally, Advisor Group Holdings Inc. lifted its holdings in Autolus Therapeutics by 3,285.0% in the 4th quarter. Advisor Group Holdings Inc. now owns 16,925 shares of the company’s stock worth $32,000 after buying an additional 16,425 shares during the period. Hedge funds and other institutional investors own 72.83% of the company’s stock.

About Autolus Therapeutics

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.